Hypermethylated epidermal growth factor receptor (EGFR) promoter is associated with gastric cancer

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Weng, Xiaoling ^a   Zhang, Hong ^a   Ye, Junyi ^a   Kan, Mengyuan ^b   Liu, Fatao ^b   Wang, Ting ^b   Deng, Jiaying ^c   Tan, Yanfang ^a   He, Lin ^a,b,d   Liu, Yun ^a  

^a FUDAN UNIVERSITY   (China)

^b Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^d SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROMOTER REGION; STOMACH TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; STOMACH NEOPLASMS;

EID: 84929193240     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep10154     Document Type: Article

References (34)

1. Parkin, D. M., Bray, F., Ferlay, J. & Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108 (2005).
2. Cunningham, D. et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 355, 11-20, doi:10.1056/NEJMoa055531 (2006).
3. Patel, R. & Leung, H. Y. Targeting the EGFR-family for therapy: biological challenges and clinical perspective. Curr. Pharm. Des. 18, 2672-2679 (2012).
4. Ettinger, D. S. Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer. Oncologist 11, 358-373, doi:10.1634/theoncologist.11-4-358 (2006).
5. Berg, M. & Soreide, K. EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy. Discov. Med. 14, 207-214 (2012).
6. Troiani, T. et al. Targeting EGFR in pancreatic cancer treatment. Curr. Drug Targets 13, 802-810 (2012).
7. Okines, A., Cunningham, D. & Chau, I. Targeting the human EGFR family in esophagogastric cancer. Nat. Rev. Clin. Oncol. 8, 492-503, doi:10.1038/nrclinonc.2011.45 (2011).
8. Garcia, I. et al. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann. Surg. Oncol. 10, 234-241 (2003).
9. Seshacharyulu, P. et al. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin. Ther. Targets 16, 15-31, doi:10.1 517/14728222.2011.648617 (2012).
10. Bergman, Y. & Cedar, H. DNA methylation dynamics in health and disease. Nat. Struct. Mol. Biol. 20, 274-281, doi:10.1038/nsmb.2518 (2013).
11. Kim, M. A. et al. EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology 52, 738-746, doi:10.1111/j.1365-2559.2008.03021.x (2008).
12. Herbst, R. S. & Shin, D. M. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 94, 1593-1611 (2002).
13. Janmaat, M. L. & Giaccone, G. The epidermal growth factor receptor pathway and its inhibition as anticancer therapy. Drugs Today (Barc) 39 (Suppl C), 61-80 (2003).
14. Overholser, J. P., Prewett, M. C., Hooper, A. T., Waksal, H. W. & Hicklin, D. J. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 89, 74-82 (2000).
15. Garrett, T. P. et al. Antibodies specifically targeting a locally misfolded region of tumor associated EGFR. Proc. Natl. Acad. Sci. USA 106, 5082-5087, doi:10.1073/pnas.0811559106 (2009).
16. Min, J. H. et al. Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight. Cancer Chemother. Pharmacol. 68, 1099-1109, doi:10.1007/s00280-011-1737-2 (2011).
17. Pedersen, M. W., Meltorn, M., Damstrup, L. & Poulsen, H. S. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann. Oncol. 12, 745-760 (2001).
18. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139, doi:10.1056/NEJMoa040938 (2004).
19. Ekstrand, A. J., Sugawa, N., James, C. D. & Collins, V. P. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc. Natl. Acad. Sci. USA 89, 4309-4313 (1992).
20. Schwechheimer, K., Huang, S. & Cavenee, W. K. EGFR gene amplification-rearrangement in human glioblastomas. Int. J. Cancer 62, 145-148 (1995).
21. Jaenisch, R. & Bird, A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat. Genet. 33 (Suppl), 245-254, doi:10.1038/ng1089 (2003).
22. Galizia, G. et al. Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J. Surg. 31, 1458-1468, doi:10.1007/s00268-007-9016-4 (2007).
23. Lieto, E. et al. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann. Surg. Oncol. 15, 69-79, doi:10.1245/s10434-007-9596-0 (2008).
24. Anzai, H. et al. Expression of metastasis-related genes in surgical specimens of human gastric cancer can predict disease recurrence. Eur. J. Cancer 34, 558-565 (1998).
25. Koullias, G. J. et al. Increased estrogen receptor and epidermal growth factor receptor gene product co-expression in surgically resected gastric adenocarcinomas. J. Surg. Oncol. 63, 166-171, doi:10.1002/(SICI)1096-9098(199611)63:3<166::AIDJSO6>3.0.CO;2-B (1996).
26. Scartozzi, M. et al. Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. Br. J. Cancer 104, 1786-1790, doi:10.1038/bjc.2011.161 (2011).
27. Gomori, E., Pal, J., Kovacs, B. & Doczi, T. Concurrent hypermethylation of DNMT1, MGMT and EGFR genes in progression of gliomas. Diagn Pathol. 7, 8, doi:10.1186/1746-1596-7-8 (2012).
28. Castelo-Branco, P. et al. Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. Lancet Oncol. 14, 534-542, doi:10.1016/S1470-2045(13)70110-4 (2013).
29. Loeb, D. M. et al. Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. Cancer Res. 61, 921-925 (2001).
30. Kelavkar, U. P. et al. DNA methylation paradigm shift: 15-lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation. Prostaglandins Other Lipid Mediat 82, 185-197, doi:10.1016/j. prostaglandins.2006.05.015 (2007).
31. Ideraabdullah, F. Y., Vigneau, S. & Bartolomei, M. S. Genomic imprinting mechanisms in mammals. Mutat. Res. 647, 77-85, doi:10.1016/j.mrfmmm.2008.08.008 (2008).
32. Bell, A. C. & Felsenfeld, G. Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene. Nature 405, 482-485, doi:10.1038/35013100 (2000).
33. Hark, A. T. et al. CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature 405, 486-489, doi:10.1038/35013106 (2000).
34. Bell, A. C., West, A. G. & Felsenfeld, G. The protein CTCF is required for the enhancer blocking activity of vertebrate insulators. Cell 98, 387-396 (1999).